RUO PROS · PRIVATE REVIEW BRIEF

Private review.
Next-step materials.

A private working brief for a structured follow-up review. Operating materials, submitted financials, source documents and external references are assembled here so the factual record can be examined before the next conversation.

Review materials ↓ Download updated P&L ↗
PRIVATE & CONFIDENTIAL · Prepared for a structured follow-up review.

PRIVATE REVIEW BRIEF

The record
for the next step.

This page consolidates the material that extends the interactive pitch: submitted financial context, source-document access, operating detail, testing exhibits and a practical review order. It is not an offer, forecast, recommendation or promise of results.

USD 3.70mLedger GMV1 Apr–12 Oct 2026 · ledger basis
USD 3.14mNet revenue1 Apr–12 Oct 2026 · unaudited accrual
USD 1.66mContribution profitApr–Sep only · before overhead
01
Financial basis

Review the updated monthly P&L v2 and the supporting ledger tie-out before relying on any summary metric.

02
Revenue reconciliation

GMV, charged amounts, discounts, refunds, fees and transactions are described as reconciled to the source ledger in the workbook.

03
Cost & expense basis

Review standard-cost inputs and the July–September budget figures against closed books before drawing an operating-profit conclusion.

Updated P&L v2: 1 April–12 October 2026; unaudited and accrual basis. October is month-to-date only. August–October sales tax includes a stated estimate, product cost is a stated standard-cost estimate, and selected July–September expenses are budget figures pending closed books and stated restatement. Contribution profit excludes October because cost and fulfilment inputs are not populated for the month-to-date period.

01

THE PEOPLE

THE PEOPLE

Meet the founder,
in his own words.

William Kasel has been building technology companies since 2008. Before RUO Pros, he built systems for Genentech, Biogen, NBCUniversal and Paramount, grew a consumer app to approximately 12 million users, went through 500 Startups, and built and sold a company, Peek, in 2021.

His work has been covered by TechCrunch, CNN and Wired; he was also a primary source for Means of Control, by Pulitzer Prize–winning author Byron Tau.

WILLIAM KASEL · RECORDED DIRECTLY

CO-FOUNDER & CTO

William Kasel

  • Technology founder since 2008; built for Genentech, Biogen, NBCUniversal and Paramount.
  • MyPad reached approximately 12M users; 500 Startups company.
  • Built and sold Peek (2021); co-founded TappLocal—read the 2010 coverage.

CO-FOUNDER · BUSINESS OPERATIONS

Megan Kasel

  • 10+ years in corporate retail; Director of Global Omnichannel Merchandising at Banana Republic and Old Navy.
  • Co-founder of Greenbox, Foreplay Golf and DSCO, the parent technology company behind this program.
  • View the Pulitzer citation.
02

THE GUARANTEE

THE GUARANTEE

The buyback, explained plainly—
then read the fine print.

The most common question after the call is how the guarantee works and what it rests on. William answers directly, and the refund-policy explanation is shown alongside the operative caveats.

Read this alongside the video. Any buyback is a contractual term with stated conditions and mechanics. It is not a guarantee of investment returns, and “de-risking” refers to operating work and execution—not the removal of financial risk.

READRisk & disclosure recordJump to Section 08 →
REFUND POLICY · EXPLAINED BY WILLIAM
03

THE SOFTWARE

THE SOFTWARE

The platform
your brand runs on.

This is the actual software stack—the same backend that powers the live stores. The walkthrough is recorded by William Kasel, screen by screen.

Prefer full screen? Open the original on Loom ↗

04

THE ECOSYSTEM

THE ECOSYSTEM

One operating company.
Six properties to inspect.

The operating stack is public and linked below. Each destination opens independently in a new tab so it can be inspected as a customer or diligence recipient would.

01RUO ProFront-end brand 02Loop Bio LabsOperating flagship 03PolymerFulfilment & wholesale 04DSCOTechnology & IP 05Leo ResearchResearch portal 06DemoResearchLive demo store
DSCO builds the software→Polymer manufactures & fulfils→RUO Pro / Loop Bio Labs sell→Leo Research handles the research layer

Direct access: Leo Research login ↗

05

LIVE REVENUE

LIVE REVENUE

Fifty-four consecutive weeks
of GMV evidence.

Weekly revenue screenshots taken directly from live stores, presented as a dated, consecutive archive from September 2025 through September 2026.

Open interactive model ↗
54-WEEK SOURCE ARCHIVESeptember 2025 → September 2026View gallery
UPDATED SUPPORTING DOCUMENTLoop Bio Labs, LLC · Monthly P&L v21 April–12 October 2026 · unaudited, accrual · October MTD
Download updated P&L ↓
06

LAB TESTING

PRODUCT VERIFICATION

Third-party tested—
verifiable by you.

Janoshik laboratory test report for Alpha BioMed batch 25M047Open original report ↗

JANOSHIK TEST REPORT

Verify the source in 30 seconds.

Report: Alpha BioMed · sample ATX-304 · batch 25M047 · conducted 10 Feb 2026. The source page states the report can be checked directly with Janoshik.

UNIQUE KEY3YHWN2LESWSR
Verify with Janoshik ↗

A COA verifies tested batch contents and quantity. It is a quality document, not a therapeutic claim.

07

MORE FROM WILLIAM

MORE FROM WILLIAM

The questions everyone asks,
answered on camera.

Five additional recordings covering common questions after the call. Open any card to play the source recording directly in the browser.

01I’ve been burned by agencies before. How is this different?Play recording
02How much does this cost to start, and are there ongoing costs?Play recording
03How long until I see revenue?Play recording
04What happens if it doesn’t work? Do you guarantee results?Play recording
05How do you make money if I’m the owner?Play recording
08

COMPLIANCE & GOVERNANCE

COMPLIANCE & GOVERNANCE

Built to be run as
what it actually is.

The authoritative source describes an operator-run structure and notes that its framework is being finalized with qualified securities counsel. The following points are presented as the source page’s diligence framework, not as legal advice.

SECURITIES POSTURE

  • Regulation D private-placement path under counsel review.
  • Private Placement Memorandum with stated risk factors.
  • Accredited-investor verification and Form D / state filing process at close.

CONSUMER PROTECTION

  • FTC business-opportunity disclosure and earnings-claim statement where figures are shown.
  • RUO discipline: no human-use, dosing or therapeutic claims.
  • TCPA, auto-renewal and endorsement compliance centrally run.

CAPITAL & PROTECTION

  • Investor capital segregated from operating cash.
  • Subscription agreement, accredited questionnaire and AML/KYC.
  • Product-liability, E&O and D&O insurance; documented tax character of profit share.
THE QUESTION EVERYONE ASKS

“Could I get myself into legal risk getting into this industry?”

The source’s direct answer acknowledges real regulatory risk and frames the diligence question around whether the operation is built to manage it.

Read the complete answer ↗
09

MARKET & EDUCATION

MARKET CONTEXT & EDUCATION ONLY

Understand the category.
Not a human-use claim.

REQUIRED READING BEFORE PLAYING ANY VIDEO

These videos are education and regulatory context only.

They are included solely to help a general audience understand peptide research, terminology and the regulatory conversation. They do not make or imply a claim about product safety, efficacy, diagnosis, treatment, dosing, suitability or human use. They are not medical advice, legal advice or product promotion. Any viewpoint belongs to the original publisher.

The figures below describe adjacent published markets, not a market-size claim for RUO Pros. Peptide therapeutics, peptide synthesis and a research-supply business have different definitions. The figures are kept separate and linked to their publisher so readers can inspect the original methodology.

80+peptide drugsWorldwide; 2022 literature review
170+in active developmentWorldwide; 2022 literature review
USD 164.0B2026 therapeutics estimateThird-party estimate; not RUO-specific
ContextPublished statisticInterpretation
Peptide therapeuticsUSD 140.9B (2025); USD 164.0B (2026); USD 294.6B (2033); 8.7% CAGRGrand View Research estimate. Therapeutics market; not a proxy for RUO Pros TAM.
Peptide synthesisUSD 961.4M (2024); USD 1.84B (2033)Separate market definition. It must not be added to therapeutics figures.
Scientific development80+ marketed peptide drugs; 170+ in active clinical development2022 peer-reviewed literature context; not product, legal or commercial evidence for a specific company.
01Grand View Research · peptide therapeuticsPublished June 2026 · third-party market estimate ↗ 02Grand View Research · peptide synthesisPublished June 2025 · third-party market estimate ↗ 03Wang et al. (2022) · therapeutic peptides reviewPeer-reviewed scientific background ↗ 04FDA · Unapproved DrugsGeneral risk context; not legal advice ↗

EDUCATION AND REGULATORY CONTEXT

Four playable sources, each clearly fenced.

PEPTIDE EDUCATION · THIRD PARTY

Peptide science & research discussion

Educational context only. No medical, diagnostic or human-use recommendation is adopted from this source.

Open original on YouTube ↗
WHAT ARE PEPTIDES? · EDUCATION ONLY

General peptide terminology

Included to help viewers understand the subject at a high level. It is not a statement about any RUO Pros product or any human use.

Open original on YouTube ↗
REGULATORY DISCUSSION · NOT LEGAL ADVICE

Attorney-supplied regulatory context

This is a supplied external discussion, not a legal opinion for a recipient, transaction, product, label, jurisdiction or use case.

Open original on YouTube ↗
RESEARCH-USE DISCUSSION · NOT LEGAL ADVICE

RUO / research-use commentary

Third-party commentary for education only. It does not determine legality, compliance, safety, efficacy or intended use for any product.

Open original on YouTube ↗

Regulatory boundary: FDA’s “For Research Use Only. Not for use in diagnostic procedures” wording is specific to certain laboratory-phase IVD products. It is not a blanket classification for peptides or a legal conclusion about a product. See the FDA labeling page ↗; obtain qualified product- and jurisdiction-specific counsel.

10

HANDBOOK & TEST EXHIBITS

CLIENT OPERATING MATERIALS · SOURCE PROVIDED

The handoff is documented.
Read the operating detail.

DOCUMENT STATUS

The handbook is a guide—not the agreement.

The supplied eight-page Client Handbook says that signed Client Services Agreements and their exhibits control where they differ, and that nothing in the guide is a promise of sales, income or results. This site presents the document as company-provided operating material, not as an independently verified contractual, financial or legal representation.

PRIMARY SOURCE DOCUMENT

Client Handbook
Your first 90 days

Supplied as RUOPRO-HANDBOOK · v1.8 · 5 Oct 2026 · current through CSA v9.24 in the page footer. It covers contacts, visible build gates, agency disclosure, supply/fulfilment, money flows, operating rules and the first twelve months.

Download Client Handbook ↓
01

Visible gates

The source describes entity, intake, processor, domain, store, supply, agency approval and Go-Live gates. It says the stated 30-day Go-Live commitment starts only after processor approval and may pause for client-side or agency-side work.

02

Agency disclosure

The handbook says the client hires and pays the advertising agency. It discloses a default affiliated agency, says another qualified agency may be used, and describes written client approval and a Compliance Hold process.

03

Money & reporting

The source describes client-owned media budgets, stated platform-fee and profit-share mechanics, reinvestment and a recoup tracker. Confirm all terms, calculations and conditions in signed documents and underlying records.

SUPPLIED CLIENT REFERENCE VIDEO · SOURCE CONTEXT ONLY

Client onboarding / operating reference

This video was supplied for the evidence room. It is not adopted as a promise of sales, income, results, timing, legal compliance, product quality or any human-use outcome. Read the complete handbook and controlling signed documents for the actual terms.

Open original on YouTube ↗

SUPPLIED TESTING EXHIBITS

Source documents for inspection—not product claims.

These screenshots were supplied by the user and are displayed without independent authentication, chain-of-custody review, lot reconciliation or methodological validation. They are not medical, safety, efficacy, dosing, human-use, product-promotion or legal claims.

Supplied Freedom Diagnostics certificate of analysis exhibitOpen full exhibit ↗

FREEDOM DIAGNOSTICS · SUPPLIED EXHIBIT

Retatrutide 20mg certificate

The displayed document identifies Loop Bio Labs LLC, lot S260923L, report date 6 Oct 2026 and a displayed purity figure of 99.84%. The exhibit itself states testing is informational research use only and not approved for human or veterinary applications.

Supplied Vanguard Laboratory certificate of analysis exhibitOpen full exhibit ↗

VANGUARD LABORATORY · SUPPLIED EXHIBIT

Semax 10 mg certificate

The displayed certificate identifies The Loop, lot LS10-0523 and report date 20 Jul 2026, with displayed chromatographic-purity and assay values. Its own text says the laboratory cannot confirm sample authenticity or representativeness of an associated lot or batch.